Herantis’s ‘Elegant’ Approach In Parkinson’s

Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.

Episode metadata supplied by the publisher feed · Published Jan 21, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Herantis’s ‘Elegant’ Approach In Parkinson’s

0:00 20:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 20 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on January 21, 2026.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!